(Q54335757)

English

Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.

scientific article published on 27 May 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

author name string

Yonghyun Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

Hyunjeong Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

Wooseong Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

Jeong-Hyun Yoon

4

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

Seong Hoon Jeong

5

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

Yunjin Jung

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

publication date

27 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

Journal of Drug Targeting

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

20

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

524-534

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

Celecoxib for the prevention of colorectal adenomatous polyps

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Cardiovascular risk associated with celecoxib

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Gastrointestinal parameters that influence oral medications

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Coxibs and cardiovascular disease

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

What should be considered on design of a colon-specific prodrug?

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Does celecoxib use increase the risk of cardiovascular events?

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Microbially triggered drug delivery to the colon

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2012.693498

21 January 2018

Identifiers

10.3109/1061186X.2012.693498

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22632102

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54335757&oldid=806174751"